ZURZUVAE (zuranolone) CIV, a landmark treatment for women with postpartum Depression, available in the U.S.
On Dec. 14, 2023, Biogen and Sage Therapeutics announced ZURZUVAE (zuranolone) 50 mg (two 25 mg capsules per…
U.S. FDA approved ZURZUVAE (zuranolone), the First and only oral treatment for Women with postpartum depression
On Aug. 4, 2023, Biogen and Sage Therapeutics announced that the U.S. Food and Drug Administration (FDA) had…
Postpartum depression may persist three years after giving birth
On Oct. 27, 2020, a National Institutes of Health (NIH) study of 5,000 women found that approximately 1…
NeoGenomics expanded global footprint in pharma services with new clinical research laboratory in Suzhou, China
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
Oxford Immunotec announced FDA clearance of the T-SPOT.TB test for use in pediatrics over the age of two
On Sept. 29, 2020, Oxford Immunotec announced that it had received clearance from the FDA to amend the…
The North Carolina Eshelman School of Pharmacy received $100 million donation from Fred Eshelman
On Dec. 3, 2014, Fred Eshelman, CEO and founder of Wilmington-based PPD Inc. and a member of the…
The North Carolina School of Pharmacy was renamed in honor of Fred Eshelman
On May 21, 2008, the North Carolina School of Pharmacy was renamed the Eshelman School of Pharmacy in…